BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pak VN. Selective targeting of myeloid-derived suppressor cells in cancer patients through AFP-binding receptors. Future Sci OA 2019;5:FSO321. [PMID: 30652015 DOI: 10.4155/fsoa-2018-0029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Lin B, Dong X, Wang Q, Li W, Zhu M, Li M. AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers. Front Cell Dev Biol 2021;9:635476. [PMID: 33898423 DOI: 10.3389/fcell.2021.635476] [Reference Citation Analysis]
2 Pak VN. The possible drug for cancer and metastasis prevention. Future Drug Discovery. [DOI: 10.4155/fdd-2022-0008] [Reference Citation Analysis]
3 Zamorina SA, Shardina KY, Timganova VP, Bochkova MS, Uzhviyuk SV, Raev MB, Chereshnev VA. Effect of Alpha-Fetoprotein on Differentiation of Myeloid Supressor Cells. Dokl Biochem Biophys 2021;501:434-7. [PMID: 34966967 DOI: 10.1134/S1607672921060077] [Reference Citation Analysis]
4 Pak VN. α-fetoprotein-binding toxins and teratogens against cancer. Ther Deliv 2019;10:1-3. [PMID: 30730821 DOI: 10.4155/tde-2018-0068] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Gulevskyy OK; Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv. URRENT CONCEPT OF THE STRUCTURAL AND FUNCTIONAL PROPERTIES OF ALFA-FETOPROTEIN AND THE POSSIBILITIES OF ITS CLINICAL APPLICATION. Biotechnol acta 2021;14:25-37. [DOI: 10.15407/biotech14.01.025] [Reference Citation Analysis]
6 Sedky HA, Youssef SR, Gamal DA, Houssein HF, Elsalakawy WA. First report of the unique expression of RECAF (receptor for alfa feto-protein) in adult B-NHL/CLL patients. Blood Res 2020;55:253-61. [PMID: 33303704 DOI: 10.5045/br.2020.2020070] [Reference Citation Analysis]